期刊文献+

利拉鲁肽对胰岛素强化治疗后初诊2型糖尿病患者体重指数、腰臀比的影响 被引量:7

下载PDF
导出
摘要 目的探讨初发2型糖尿病肥胖患者经胰岛素泵强化治疗1周后使用利拉鲁肽治疗对其体型的影响。方法 30例初发2型糖尿病肥胖患者经胰岛素强化治疗后将之随机分为观察组与对照组,两组患者在加强饮食、运动控制的基础上,观察组使用门冬胰岛素30控制血糖的同时给予利拉鲁肽皮下注射治疗;对照组仅采用门冬胰岛素30控制血糖,观察两组患者HBA1C、WHR、BMI水平的变化。结果观察组患者各项观察指标优于对照组,差异具有统计学意义(P<0.05)。结论初发2型糖尿病肥胖患者于胰岛素强化治疗后使用利拉鲁肽治疗,可有效改善肥胖患者体型。
出处 《内科》 2013年第6期606-606,603,共2页 Internal Medicine
  • 相关文献

参考文献3

  • 1UK Prospective DiabetesStudy(UKPDS)Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).UK Prospective Diabetes Study (UKPDS) Group[J].1ancet,1998,(9131):854-865.
  • 2苏培.2型糖尿病治疗新药——利拉鲁肽[J].天津药学,2012,24(3):53-56. 被引量:11
  • 3Yang W,Liu X,Ma J. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China,South Korea and India:a 16-week,randomized,double-blind,active control trial(*)[J].{H}Diabetes Obesity & Metabolism,2011,(01):81-88.

二级参考文献22

  • 1Gallwitz B. Glucagon - like peptide - 1 as a treatment option for type 2 diabetes and its role in restoring beta - cell mass. Diabetes Technol T- her,2005,7(4) :651.
  • 2Buteau J, El - Assaad W, Rhodes C J, et al. Glucagon - like peptid - 1 prevents beta cell glucolipotpxicity. Diabet - ologia,2004,47 (5) : 806.
  • 3Iwai T, Suzuki M, Kobayashi K, et al. The influences of juvenile diabe- tes on memory and hippocampal plasticity in rats: improving effects of glucagon - like peptide - 1. Nenrosci Res,2009,64( 1 ) :67.
  • 4Matthews D R, Mane M, Le Thi T D, et al, Liraglutide,a human GLP - 1 analogue, significantly improves beta - cell function in subjects with type 2 diabetes. Diabetologia, 2008,51 : 892.
  • 5Matthews D. Liraglutide improves β -cell function as assessed by HO-MA - B and proinsulin : insulin ratio - meta analysis of six clinical tri- als. Diabetes ,2010,59 (s) : 1513.
  • 6Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride ( both in combination with mefformin ) and re- duces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16 -week, ran- domized, double -blind, active control trial. Diabetes Obes Metab, 2011,13:81.
  • 7Yang W, Liu X, Ma J, et al. Liraglutide provides similar glycemic con- trol with reduced systolic blood pressure and body weight compared to glimepiride when added to metformin in Chinese subjects with T2D. Di- abetes, 2010, 59 (s) : 190.
  • 8Dharmalingam M, Sriram U, Baruah M P. Liraglutide: A review of its therapeutic use as a once daily GLP - 1 analog for the management of type 2 diabetes mellitus. Indian J Endocrinol Metab, 2011, 15:9.
  • 9Garber A, Henry R, Rather R, et al. Liraglutide versus glimepiride montherapy for type 2 diabetes ( LEAD - 3 Mono) : a randomised, 52 - week, phase 3, double - blind parallel - treatment trial. Lancet, 2009,373 (9662) :473.
  • 10Gather A, Henry R R, Ratner R,et al. Liraglutide, a once - daily hu- man glucagon - like peptide 1 analogue, provides sustained improve- ments in glycaemic control and weight for 2 years as monotherapy com- pared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab, 2011, 13:348.

共引文献10

同被引文献57

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部